Chickenpox Clinical Trial
Official title:
Safety and Immunogenicity Study of 2 Formulations of GSK Biologicals' Varicella Vaccines Given as a 2-dose Course in the Second Year of Life.
Verified date | November 2019 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and immunogenicity of 2 formulations of GSK Biologicals' varicella vaccines given as a 2-dose course in the second year of life.
Status | Completed |
Enrollment | 1236 |
Est. completion date | October 25, 2016 |
Est. primary completion date | October 25, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Months to 23 Months |
Eligibility |
Inclusion Criteria: - Subjects' parent(s)/ LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol. - A male or female between, and including, 12 and 23 months of age (i.e. 12 months to a day before 24 months) at the time of the first study vaccination. - Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure. - Subjects in stable health as determined by investigator's clinical examination and assessment of subject's medical history. - Subjects must have had prior administration of a dose of measles, mumps and rubella (MMR) vaccine at least 30 days (Day -31 or earlier) prior to study vaccination at Day 0. Exclusion Criteria: - Child in care. - Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the day of study vaccination (i.e., 30 days prior to Visit 1/Day 0) or planned use during the entire study period. - Concurrently participating in another clinical study, in which the child has been or will be exposed to an investigational or a non-investigational product. - Chronic administration (defined as 14 or more consecutive days) of immunosuppressants, or other immune-modifying drugs during the period starting 180 days prior to the first vaccine dose or any planned administration of immunosuppressive and immune-modifying drugs during the entire study. - For corticosteroids, this will mean prednisone =0.5 mg/kg/day or equivalent. - Inhaled and topical steroids are allowed. - Planned administration/ administration of a live viral vaccine not foreseen by the study protocol during the period starting 30 days prior to study vaccination at Visit 1/Day 0 until study end. Non study live viral vaccines can be administered at Visit 3 (Day 84) after completion of study procedures. - Planned administration/ administration of an inactivated vaccine not foreseen by the study protocol during the period starting 7 days prior to each vaccination (at Visit 1/Day 0 and Visit 2/Day 42) and ending 14 days after each vaccination. Outside of this period, non-study inactivated vaccines can be administered as per standard of care. - Administration of immunoglobulins and/or any blood products during the period starting 180 days prior to the first vaccine dose or planned administration from the date of first study vaccination through the entire study. - History of varicella or zoster. - Known exposure to varicella/zoster during the period starting within 30 days prior to first study vaccination. - Previous vaccination against varicella. - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). - Subjects with blood dyscrasias, leukemia, and lymphomas of any type. - A family history of congenital or hereditary immunodeficiency - History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including hypersensitivity to neomycin or latex. - Major congenital defects or serious chronic illness. - Acute disease and/or fever at the time of enrolment. - Fever is defined as temperature =38. 0°C/100.4°F by any age appropriate route. - Subjects with a minor illness without fever may be enrolled at the discretion of the investigator. - Active untreated tuberculosis based on medical history. - Any other condition which, in the opinion of the investigator, prevents the child from participating in the study. |
Country | Name | City | State |
---|---|---|---|
Estonia | GSK Investigational Site | Tallinn | |
Estonia | GSK Investigational Site | Tallinn | |
Estonia | GSK Investigational Site | Tartu | |
Germany | GSK Investigational Site | Aschaffenburg | Bayern |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Detmold | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Frankenthal | Rheinland-Pfalz |
Germany | GSK Investigational Site | Kehl | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Neumuenster | |
Germany | GSK Investigational Site | Schoenau Am Koenigssee | Bayern |
Germany | GSK Investigational Site | Solingen | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Stuttgart | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Stuttgart | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Tauberbischofsheim | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Vellmar | Hessen |
Germany | GSK Investigational Site | Wurzen | Sachsen |
Mexico | GSK Investigational Site | Merida | Yucatán |
Mexico | GSK Investigational Site | Mexico city | |
Thailand | GSK Investigational Site | Bangkok | |
United Kingdom | GSK Investigational Site | Bristol | |
United Kingdom | GSK Investigational Site | London | |
United Kingdom | GSK Investigational Site | Oxford | |
United Kingdom | GSK Investigational Site | Southampton |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Estonia, Germany, Mexico, Thailand, United Kingdom,
Faust SN, Le Roy M, Pancharoen C, Weber MAR, Cathie K, Behre U, Bernatoniene J, Snape MD, Helm K, Medina Pech CE, Henry O, Baccarini C, Povey M, Gillard P. Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study. BMC Pediatr. 2019 Feb 7;19(1):50. doi: 10.1186/s12887-019-1425-7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects Reporting Fever | Fever was defined as axillary temperature above (>) 39.0 °C (> 102.2°F) | 15-days (Days 0-14) post Dose 1 of varicella vaccination | |
Secondary | Number of Subjects Reporting Fever | Fever was defined as axillary temperature greater than or equal to (=) 38.0°C (= 100.4°F) | 15 days post each dose of varicella vaccination | |
Secondary | Evaluation of Immune Response to Varicella Vaccine With Respect to Anti Varicella Zoster Virus (Anti-VZV) Antibody Concentrations (Immuno-sub Cohort) | Anti-VZY antibody concentrations were expressed in terms of Geometric Mean Concentrations (GMCs) | At Day 42 and Day 84 post vaccination | |
Secondary | Number of Subjects With a Seroresponse to VZV (Immuno Sub Cohort) | For VZV, seroresponse was defined as, post-vaccination anti-VZV antibody concentration = 50 mIU/mL among subjects who were seronegative (antibody concentration below (< ) 25 mIU/mL) before vaccination | At Day 42 and Day 84 post vaccination | |
Secondary | Number of Subjects Reporting Solicited Local Symptoms | Solicited local symptoms assessed were pain, injection site redness and swelling. Any = occurrence of the specified solicited local symptom regardless of its intensity. Grade 3 pain = subject crying when limb was moved or as spontaneously painful. Grade 3 redness and swelling = above (>) 20 mm | 4-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42) | |
Secondary | Number of Subjects Reporting Fever | Any fever (= 38°C) = occurrence of any fever regardless of its intensity grade or relationship to vaccination. Grade 3 fever = temperature > 39.5°C. Related fever = assessed by the investigator as causally related to study vaccination | 43-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42) | |
Secondary | Number of Subjects Reporting Rash | Any rash = occurrence of the specified solicited general symptom regardless of its intensity. Grade 3 rash = rash which prevented normal, everyday activities. Related rash = assessed by the investigator as causally related to study vaccination | 43-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42) | |
Secondary | Number of Subjects Reporting Febrile Convulsions | Any febrile convulsion = occurrence of the specified solicited general symptom regardless of its intensity. Grade 3 febrile convulsion = febrile convulsion which prevented normal, everyday activities. Related febrile convulsion = assessed by the investigator as causally related to study vaccination | 43-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42) | |
Secondary | Number of Subjects Reporting Unsolicited Adverse Events (AEs) | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination | 43-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42) | |
Secondary | Number of Subjects Reporting Serious Adverse Events (SAEs) | SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalisation or prolongation of hospitalisation or resulted in disability/incapacity. Any SAE = occurrence of SAE regardless of intensity grade or relation to vaccination | From Day 0 through the end of study (Day 84) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01887496 -
Varicella-related Hospitalizations in Turkey
|
N/A | |
Completed |
NCT00326183 -
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
|
Phase 4 | |
Completed |
NCT02452229 -
Review of Human Herpes Viruses in Burns
|
N/A | |
Completed |
NCT01815073 -
Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine
|
Phase 4 | |
Completed |
NCT01817270 -
Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine
|
Phase 4 | |
Active, not recruiting |
NCT01982409 -
Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children
|
Phase 4 | |
Completed |
NCT00921999 -
Immune Response to Varicella-Zoster Vaccination and Infection
|
N/A | |
Completed |
NCT00098046 -
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
|
Phase 3 | |
Completed |
NCT05732337 -
Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device.
|
N/A | |
Completed |
NCT01684072 -
Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin
|
Phase 4 | |
Completed |
NCT00156559 -
MMR and Varicella Vaccine in Premature Infants
|
Phase 4 | |
Active, not recruiting |
NCT05084508 -
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
|
Phase 2 | |
Completed |
NCT04384016 -
Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old
|
Phase 4 | |
Completed |
NCT00000953 -
Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients
|
Phase 2 | |
Completed |
NCT00002358 -
A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
|
Phase 3 | |
Completed |
NCT00002315 -
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
|
Phase 3 | |
Completed |
NCT00001125 -
Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox
|
Phase 1 | |
Withdrawn |
NCT00001054 -
The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children
|
Phase 1 |